At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 204 enrolled
Drug / intervention
LY2157299 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating LY2157299, Sorafenib, and 1 other intervention for Carcinoma, Hepatocellular. Completed, enrolled 204 participants across 40 sites in 7 countries.
Detailed Summary
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular
CountriesAustralia, France, Germany, Italy, New Zealand, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartMar 2011
Primary CompletionJun 2019
Study CompletionDec 2019
TodayJul 2026
First PostedNov 24, 2010
Enrollment StartMar 30, 2011
Primary CompletionJun 6, 2019
Study CompletionDec 24, 2019
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 15.6 years ago
Interventions
LY2157299drug
Administered orally
Sorafenibdrug
Administered orally
Ramucirumabdrug
Administered IV